News 2/16

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

ipharmaservices

Nov 19

Top 10 pharmaceutical companies by revenues | 2025 | iPharmaCenter

Badari Andukuri

Nov 18

American College of Rheumatology (ACR) Convergence | Chicago | 2025 | iPharmaCenter

ipharmaservices

Oct 28

Novo Nordisk Acquires Akero Therapeutics for $4.7 Billion, Expanding Its MASH Portfolio with First-in-Class FGF21 Analogue

ipharmaservices

Oct 16

FDA Approves Johnson & Johnson’s Simponi (golimumab) as the First Monthly Maintenance Therapy for Pediatric Ulcerative Colitis

ipharmaservices

Oct 9

Daiichi Sankyo Advances Breast Cancer Portfolio Expansion with ENHERTU approaval in Japan and DATROWAY's positive study

ipharmaservices

Oct 8

Novartis Ushers in a New Era with FDA Approval of Rhapsido (Remibrutinib) for Chronic Spontaneous Urticaria

ipharmaservices

Oct 8

AbbVie's Latest Clinical Trial for Alopecia Areata Shows Positive Results | iPharmaCenter

ipharmaservices

Aug 25

FDA Clears Novo Nordisk’s Wegovy for MASH Treatment | iPharmaCenter

ipharmaservices

Aug 19

FDA Approves GSK’s Nucala for COPD Patients with Eosinophilic Inflammation

ipharmaservices

May 28

Top Drug Launches to Watch in 2025 | iPharmaCenter

ipharmaservices

Feb 16

Novartis Strengthens Cardiovascular Portfolio with $3.1 Billion Anthos Therapeutics Acquisition | iPharmaCenter

ipharmaservices

Feb 11

Top selling drugs of 2024 | Best selling drugs of 2024 | iPharmaCenter

ipharmaservices

Feb 6

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

ipharmaservices

Feb 3

European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter

ipharmaservices

Feb 3

Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter

ipharmaservices

Feb 2

Roche’s Itovebi Combination Therapy Shows Significant Survival Benefit in Advanced PIK3CA-mutated, HR-positive, HER2-negative Breast Cancer | iPharmaCenter

ipharmaservices

Jan 29

American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium | iPharmaCenter

ipharmaservices

Jan 25

Sarclisa Receives EU Approval as First Anti-CD38 Therapy for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

ipharmaservices

Jan 25

Novo Nordisk Unveils Promising Higher-Dose Semaglutide Results for Obesity After CagriSema Setback | iPharmaCenter

ipharmaservices

Jan 23